Cargando…
Lubiprostone for the Treatment of Adult Women with Irritable Bowel Syndrome with Constipation
Irritable bowel syndrome with constipation (IBS-C) affects approximately 5% of the population in western countries. The majority of those afflicted are women. Symptoms are often detrimental to the individual’s quality of life and incur high healthcare costs to society. There is no evidence to suppor...
Autores principales: | Soubra, Mahmoud, Schey, Ron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987758/ https://www.ncbi.nlm.nih.gov/pubmed/24833931 http://dx.doi.org/10.4137/CGast.S7625 |
Ejemplares similares
-
Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome
por: Lunsford, Tisha N, et al.
Publicado: (2010) -
Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
por: Chang, L., et al.
Publicado: (2016) -
Lubiprostone: a novel treatment for chronic constipation
por: Lacy, Brian E, et al.
Publicado: (2008) -
A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly
por: Gras-Miralles, Beatriz, et al.
Publicado: (2013) -
Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
por: Iorio, Natalya, et al.
Publicado: (2015)